Health & Wellness
One in three people in Britain can expect to suffer from some form of allergy during their lifetime - including 2 million people in the UK thought to have some allergy to food - but there has been barely any increase in NHS services to cope with this. Experts will warn this week that demand for care is outstripping the NHS's ability to cope, and many patients go to private clinics or dietitians that may offer unconventional diets.
Fourteen people in six Western states have fallen ill after eating the beef but all have recovered, the department said.
The exceptional spring weather, which is forecast to continue into next week with a high of 24C today, will offer the best opportunity so far this year to top up D-levels that have become depleted over the winter, scientists say.
Vitamin D is created by the action of sunlight on the skin and levels in all UK residents are at their lowest at this time of year, after the long winter. Short days and cloudy skies mean 60 per cent of the British population are deficient by the start of spring.
The petition, which was submitted to the federal Environmental Protection Agency, also called for studies of human risks related to the dirt-lifting agents called nonylphenol ethoxylates, or NPEs.
TB can usually be treated with a course of four standard, or first-line, anti-TB drugs. If these are misused or mismanaged, multidrugresistant TB (MDR-TB) can develop. MDR-TB takes longer to treat with second-line drugs, which are more expensive and have more side-effects. If these drugs are also misused or mismanaged, extensively drug-resistant TB (XDR-TB) can develop. Because XDR-TB is resistant to first- and second-line drugs, treatment options are seriously limited and so are the chances of cure.
5 SEPTEMBER 2006 - GENEVA - The World Health Organization (WHO) has expressed concern over the emergence of virulent drug-resistant strains of tuberculosis (TB) and is calling for measures to be strengthened and implemented to prevent the global spread of the deadly TB strains. This follows research showing the extent of XDR-TB, a newly identified TB threat which leaves patients (including many people living with HIV) virtually untreatable using currently available anti-TB drugs.
Later this week, WHO will join other TB experts at a two-day meeting in South Africa (7-8 September) to assess the response required to critically address TB drug resistance, particularly in Africa, and will take part in a news conference scheduled for Thursday, 7 September in Johannesburg.